Interneuron Data On Dexfenfluramine
Interneuron has reported that its trials with dexfenfluramine in obese patients have provided data at one year showing statistically-significant sustained weight loss compared to placebo, and meet the standards recommended by the US Food and Drug Administration's Endocrinologic and Metabolic Drugs Advisory Committee.
The company carried out 18 placebo-controlled trials, of which 17 showed statistically-significant weight loss. Bobby Sandage, Interneuron vice president of research and development, said that this "continuous weight control for one year is sufficient proof of [the drug's] long-term efficacy."
Interneuron predicts an FDA advisory committee review for the drug in the first half of this year. The drug is licensed to Lederle in the USA.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze